What is Envoy Medical's revenue?

Envoy Medical (COCH) generated $234.0K in revenue over the trailing twelve months, up 10.4% year over year.

Is Envoy Medical profitable?

Envoy Medical is not currently profitable: it reported a net loss of $23.1M over the trailing twelve months, a -9875.6% net margin.

What are Envoy Medical's profit margins?

Gross margin is -310.7% and operating margin is -9881.2%, with a -9875.6% net margin.

What is Envoy Medical's earnings per share?

Envoy Medical's diluted EPS over the trailing twelve months is $-1.01.

Where does Envoy Medical's income statement data come from?

Every line is extracted from Envoy Medical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Envoy Medical COCH Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$241K+7.1%	$225K-28.8%	$316K—	——
Total cost of revenue	$874K+17.8%	$742K-2.4%	$760K—	——
Gross profit	-$633K-22.4%	-$517K-16.4%	-$444K—	——
Gross margin	-262.7%-32.9pp	-229.8%-89.3pp	-140.5%—	——
Research and development	$12.49M+22.7%	$10.18M+13.3%	$8.99M—	——
Selling and marketing	$1.22M-29.6%	$1.73M+4.1%	$1.67M+88.2%	$885K—
General and administrative	$7.93M+16.2%	$6.83M-6.0%	$7.26M—	——
Compensation and benefits	$657K+16.9%	$562K-64.3%	$1.58M—	——
Depreciation and amortization	$302K+74.6%	$173K+30.1%	$133K—	——
Total costs & expenses	$22.51M+15.5%	$19.48M+4.3%	$18.68M+160%	$7.17M+19.7%
Operating income	-$22.27M-15.6%	-$19.26M-4.9%	-$18.36M-159%	-$7.09M-18.4%
Operating margin	-9,240.7%-682pp	-8,558.7%-2,749pp	-5,809.8%—	——
Interest expense	$1.59M+94.9%	$816K—	——	——
Other income (expense), net	-$1.49M+3.4%	-$1.54M—	——	——
Net income	-$23.76M-14.2%	-$20.8M+30.5%	-$29.92M-87.9%	-$15.92M-6,228%
Net margin	-9,857.3%-615pp	-9,242.2%+227pp	-9,469%—	——
Preferred stock dividends	$4.91M-11.1%	$5.52M—	——	——
Diluted earnings per share	-$1.22+18.1%	-$1.49+42.0%	-$2.57-165%	-$0.97-2,325%
Basic earnings per share	-$1.22+18.1%	-$1.49+42.0%	-$2.57-165%	-$0.97-782%
Weighted-average shares, diluted	87.8M+17.7%	74.6M+70.5%	43.8M-58.4%	105.2M-20.8%
Weighted-average shares, basic	87.8M+17.7%	74.6M+74.5%	42.8M-59.4%	105.2M-20.8%
Change In Fair Value Of Publicly Traded Warrant Liability	——	——	-$942K—	——
Changes In Fair Value Of Warrant Liability Due To Extension	$24K-97.3%	$881K—	——	——
Deemed Dividend On Waiver Of Restriction On Class A Common Stock	——	$495K—	——	——
Induced Conversion Of Series A Preferred Stock Into Class A Common Stock	——	$1.16M—	——	——
Loss On Offering And Change In Fair Value Of Private Warrant Liability	$494K—	——	——	——
Preferred Stock Dividends Per Share Cash Paid	——	——	——	——
Accrued And Unpaid Dividends On Series A Preferred Stock	——	——	——	——
Accrued And Unpaid Dividends Payable	——	——	——	——
Accrued Unpaid Regular Dividends	$2.63M—	——	——	——
Additional Dividends	——	——	——	——
Adjustments To Additional Paid In Capital Extinguishment Of Excess Warrant Liability Upon Exercise Of Warrants Associated With The Forward	——	$96K—	——	——
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition	$657K+16.9%	$562K-64.3%	$1.58M—	——
Issuance of warrants to purchase common stock	——	$1.4M—	——	——
Pre-tax stock-based compensation cost	——	——	$1.58M—	$0—
Amortization Of Debt Discount Premium	——	——	——	——
Amortization Of Financing Costs And Discounts	$1.59M—	——	——	——
Amortization Of Prepaid Insurance	$964K-7.9%	$1.05M+73.9%	$602K—	——
Annual Increase In Product Price Due To Inflation	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	$1.26M—	——	——
Change In Fair Value Of Private Warrant Liability	——	——	——	——
Change In Operating Lease Rightofuse Assetsrelated Party	$206K—	——	$113K—	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$23.75M-14.2%	-$20.8M+30.3%	-$29.84M—	——
Federal	-$1.89M-151%	$3.68M—	——	——
Deferred Foreign Income Tax Expense Benefit	$67K—	——	——	——
State	-$794K+27.8%	-$1.1M—	——	——
Depreciation	$302K+74.6%	$173K+30.1%	$133K—	——
Dividends on preferred shares	$4.91M-11.1%	$5.52M+309%	$1.35M—	——
Effect of exchange rate changes on cash, cash equivalents and restricted cash	——	-$5K—	——	-$7K—
Effective Income Tax Rate Changesin Unrecognized Tax Benefits	——	——	——	——
Income taxes at U.S. statutory rate of 21%	——	——	——	——
Effective Income Tax Rate Reconciliation At Germany Income Tax Rate	——	——	——	——
Effective Income Tax Rate Reconciliation Cancellation Of Debt Income Tax Benefit Percent	——	——	——	——
Effective Income Tax Rate Reconciliation Cancellation Of Debt Income Tax Benefit Amount	$6.7M—	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——
Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses	——	——	——	——
Effective Income Tax Rate Reconciliation Other Reconciling Items Percent	——	——	——	——
Effective Income Tax Rate Reconciliation Permanent Items Percent	——	——	——	——
Excess tax benefits associated with employee equity plans (in percent)	——	——	——	——
Excess tax benefits associated with employee equity plans	-$164K—	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Percent	——	——	——	——
Effective Income Tax Rate Reconciliationat Changesin Unrecognized Tax Benefits	-$1.03M—	——	——	——
Expenses Related To Shares Issued For Services	——	——	——	——
Fair Value Adjustment Of Warrants	-$534K-29.9%	-$411K—	——	-$39.22M—
Financing Of Prepaid Insurance	——	——	$1.12M—	——
Income Loss From Continuing Operations Before Income Taxes Domestic	-$23.53M-14.4%	-$20.58M—	——	——
Income Loss From Continuing Operations Before Income Taxes Foreign	-$222K-2.8%	-$216K—	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	-$800K+69.1%	-$2.59M+55.2%	-$5.78M-1,063%	$600K—
Income Tax Reconciliation Income Tax Expense Benefit At Germany Income Tax Rate	$47K—	——	——	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	-$4.99M—	——	——	——
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	$72K—	——	——	——
Accounts payable	$1.39M+7,389%	-$19K—	——	$342K—
Increase (Decrease) in Accounts Receivable	-$4K+87.5%	-$32K—	——	——
Accrued liabilities	——	——	-$94K—	——
Increase Decrease In Derivative Liabilities	-$161K+11.0%	-$181K—	——	——
Increase (Decrease) in Inventories	——	——	——	$194K—
Short- and long-term operating lease liabilities	-$239K-50.3%	-$159K—	——	——
Increase (decrease) in other current liabilities	-$868K-197%	$891K—	——	——
Increase (Decrease) in Other Receivables	-$761K—	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$868K—	——
Indebtedness For Cash Consideration	$100K—	——	——	——
Induced Conversion Of Series A Preferred Stock Into Common Stock	——	$1.16M—	——	——
Debt	$1.59M+94.9%	$816K—	——	——
Interest Paid, Excluding Capitalized Interest, Operating Activity	$36K-12.2%	$41K+57.7%	$26K—	——
LCM inventory valuation adjustment	——	——	——	——
Issuance Of Placement Agent Warrants	$391K—	——	——	——
Issuance Of Stock And Warrants For Services Or Claims	$88K—	——	——	——
Material Bad Debt Expense	$0—	$0—	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$16.63M-17.7%	$20.2M-11.2%	$22.74M+181%	$8.09M-98.1%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$179K—	——	-$153K—	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$18.2M-1.4%	-$17.95M+1.3%	-$18.19M-107%	-$8.81M-172%
Number of reportable segments	——	——	1—	——
Offering Costs From The Issuance Of Class A Common Stock And Investor Warrants From Registered	$768K—	——	——	——
Foreign currency translation gains (losses)	$3K+160%	-$5K—	——	——
Other comprehensive income (loss)	$3K+160%	-$5K—	——	——
Other income, net (Note 6)	-$23K+8.0%	-$25K—	——	——
Payments of Dividends	——	——	——	——
Payments of Financing Costs	$827K-9.7%	$916K+62.7%	$563K—	——
Payments to Acquire Property, Plant, and Equipment	$179K—	——	$153K—	——
Dividend rate of preferred stock per annum (as a percent)	——	——	——	——
Prepayment fees	——	——	$4.5M—	——
Repayment of loans by equity affiliates	——	$15M—	——	——
Proceeds from debt financing, net of issuance costs	——	——	——	——
Proceeds from Issuance of Common Stock	——	——	$109K—	——
Proceeds From Purchase Agreement Amount	——	——	——	——
Proceeds From Related Party Debt	——	$20M—	——	$1.5M—
Proceeds From Warrant Exercises	——	——	——	——
ATM Program issuances	——	——	$1.7M—	——
Stock-based compensation	$657K+16.9%	$562K-64.3%	$1.58M—	——
Standard Product Warranty Utilization	-$161K+11.0%	-$181K-42.5%	-$127K—	——
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	$1K—	——	——	——
Stock Issued During Period Value Purchase Exercise Of Forward Purchase Agreement Warrant	$3.11M+71.4%	$1.82M—	——	——
Stock Issued During Period Value Waiver Of Accrued Dividends Associated With Sponsor Support Agreement	——	$3.73M—	——	——
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions	——	$964K—	——	——
Valuation Allowance Deferred Tax Asset	$2.62M+2.5%	$2.55M—	——	——
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	-$2.62M-201%	$2.59M-55.4%	$5.8M—	——
Waiver Of Accrued Dividends Associated With Sponsor Support Agreement	——	$3.73M—	——	——
Warrants Issued With Term Loansrelated Party	——	——	——	——
EBIT	-$22.27M-15.6%	-$19.26M-4.9%	-$18.36M-159%	-$7.09M-18.4%
EBITDA	-$21.97M-15.1%	-$19.08M-4.7%	-$18.23M—	——
EBITDA	-$21.97M-15.1%	-$19.08M-4.7%	-$18.23M—	——
EBITDA margin	-9,115.4%-634pp	-8,481.8%-2,714pp	-5,767.7%—	——
EBIT	-$22.27M-15.6%	-$19.26M-4.9%	-$18.36M-159%	-$7.09M-18.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Envoy Medical.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Envoy Medical's revenue?: Envoy Medical (COCH) generated $234.0K in revenue over the trailing twelve months, up 10.4% year over year.
Is Envoy Medical profitable?: Envoy Medical is not currently profitable: it reported a net loss of $23.1M over the trailing twelve months, a -9875.6% net margin.
What are Envoy Medical's profit margins?: Gross margin is -310.7% and operating margin is -9881.2%, with a -9875.6% net margin.
What is Envoy Medical's earnings per share?: Envoy Medical's diluted EPS over the trailing twelve months is $-1.01.
Where does Envoy Medical's income statement data come from?: Every line is extracted from Envoy Medical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.